# Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

> **NCT03465059** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 29 (actual)

## Conditions studied

- Hepatic Insufficiency & Healthy Subjects

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT03465059
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2018-10-19
- **Final completion:** 2018-10-19
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465059, "Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03465059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*